NICE (UK): Keytruda (pembrolizumab) from Merck Inc., is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement in adults.
Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended...
Merck Inc. announced that the European Commission has approved Keytruda (pembrolizumab) for the adjuvant treatment of adults with stage III...
Merck Inc., announced that the FDA has approved Keytruda, Merck�s anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma...
BMS announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30...
Background: Abdominal lymph node metastasis (ALNM) is common in patients with metastatic non-small-cell lung cancer (NSCLC). However, its mechanism of spread remains to be elucidated. We investigated whether thoracic duct has the role as a pathway for ALNM in NSCLC using clinical data.
The FDA has approved on 13 March 2013, Lymphoseek (technetium Tc 99m tilmanocept) Injection, from Navidea Biopharmaceuticals , a radioactive...
We aimed to assess the diagnostic accuracy of C-11 choline and C-11 acetate positron emission tomography/computed tomography (PET/CT) for lymph node (LN) staging in bladder cancer (BC) patients through a systematic review...
The FDA has on 13 June 2014 approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection from Navidea Biopharmaceuticals,...
Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...